Pathos AI cancer drug deals worth up to $2.3 billion closed August 3, 2026, as the New York biotech licensed a dual-target TROP2/HER3 bispecific ADC from Alphamab and partnered with AstraZeneca on an oral PROTAC estrogen receptor degrader — both programs to be guided by its Foundry AI clinical trial design platform targeting a $3 billion valuation.